Find A Research Study
Study Title: Newly diagnosed, untreated ovarian or peritoneal cancer (GOG 0218)
Category: Cancer, General
Currently accepting participants?
Yes - please read the description below and contact the study coordinator if you are interested.
Principal Investigator: Thomas Malpass
Study Coordinator: Kathy Rabena
Phone: (206) 223-6892 Ext.36892
Email: hemckr@vmmc.org
What is the Newly diagnosed, untreated ovarian or peritoneal cancer (GOG 0218) study?
Arm 1 Standard Chemotherapy:
Phase A: Chemotherapy (cucles 1-6) every 3 weeks
with Paclitaxel/Docetaxel, Carboplatin and
Placebo(for Bevacizumab)(Bevacizumab cylces 2-6)
Phase B: Placebo (for Bevacizumab) every 3 weeks
cycles 7-22
Arm 2 (concurrent Bevacizumab):
Phase A: Chemotherapy (cucles 1-6) every 3 weeks
with Paclitaxel/Docetaxel, Carboplatin and
Bevacizumab cylces 2-6
Phase B: Placebo (for Bevacizumab) every 3 weeks
cycles 7-22
Arm 3(extended Bevacizumab):
Phase A: Chemotherapy (cucles 1-6) every 3 weeks
with Paclitaxel/Docetaxel, Carboplatin and
Bevacizumab cylces 2-6
Phase B: Bevacizumab every 3 weeks(cycles 7-22)
Who can participate?
Eligibility:
~Histological diagnosis of epithelial ovarian cancer or peritoneal primary carcinoma, FIGO stage III with any gross resudual diseasr or FIGO stage IV.
~Must enter in study between 1-12 weeks after inital surgerry.
Ineleigible:
~Patient with current diagnosis of borderline epithelial ovarian tumor or recurrent invasive epithelia ovarian cancer treated with surgery only.
~Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis.
~Patients who have received prior chemotherapy for any abdominal or pelvi tumor including neo-adjuvant for thier ovarian or primary peritoneal cancer.
~Histological diagnosis of epithelial ovarian cancer or peritoneal primary carcinoma, FIGO stage III with any gross resudual diseasr or FIGO stage IV.
~Must enter in study between 1-12 weeks after inital surgerry.
Ineleigible:
~Patient with current diagnosis of borderline epithelial ovarian tumor or recurrent invasive epithelia ovarian cancer treated with surgery only.
~Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis.
~Patients who have received prior chemotherapy for any abdominal or pelvi tumor including neo-adjuvant for thier ovarian or primary peritoneal cancer.
What do I have to do as a study participant?
Study Summary:
"A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carbopatin and Paclitaxel Plus Concurrent Bevacizumab Followd by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, In Women with Newl Diagnosed, Previously Untreated, Stage III or IV, Epithelial Ovarian or Primary Peritoneal Cancer"
Detailed Study Description:
(No information)
Study Design: Interventional, Blinded
Phase of Study: Phase III
Study Type: Interventional
Condition or Study Focus: Ovarian Cancer
Intervention Type: Chemotherapy
Intervention Name: Bevacizumab
Gender: Female
Age group: Interventional
Sponsor: Gynecological Oncology Group (GOG)
Other studies in this category include:
Studies currently accepting study participants:
- A Randomized Phase III Study of Sublobar Resection versus Sublobar Resection plus Brachytherapy in High Risk Patients with Non-Small Cell Lung Cancer (NSCLC),
- A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by Surgery for Selected Patients for Stage III and IV Head and Neck Carcinomas
- AMC045: HIV-Associated Anal Cancer
- AMC047: AIDS-Associated B-Cell Non-Hodgkin's Lymphoma
- Brain Metastases in NSCLC (RTOG 0320)
- Investigational drug vs. Placebo for Patients with Renal Cell Carcinoma (Kidney Cancer) at High Risk of Recurrence after Surgery
- Lymphoma (S0313)
- Maintenance therapy for advanced ovarian or peritoneal cancer (GOG 0212)
- Newly diagnosed, untreated ovarian or peritoneal cancer (GOG 0218)
- Non-Cystectomy Candidates with Muscle-Invasive Bladder Cancer (RTOG 0524)
- PGT307 - Paclitaxel Poliglumex plus Carboplatin for the treatment of non-small cell lung cancer in women.
- Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
- Sorafenib v. Sunitinib v. Placebo for High Risk Renal Cell Carcinoma Patients
- Sorafenib vs Placebo for Hepatocellular Carcinoma
- Stage IV Urothelial Cancer
- SWOG S0016
- Temsirolimus and Sorafenib as Second-Line Therapy in Patients With Advanced RCC Who Failed First-Line Sunitinib
- Trial of FOLFOX with or without cetuximab for colon cancer
- Use of Human Corticotropin-Releasing Factor (hCRF) to Control Brain Swelling (edema) in Brain Tumor Patients
- Weekly Topotecan (HyCamtin®) with Bevacizumab (Avastin®) Ovarian, Fallopian tube and/or Peritoneal Cancer
Studies currently not accepting study participants:
- Methylphenidate in Treating Patients With Fatigue Caused by Cancer
- MK0646 for Patients with Advanced Cancer
- Open Label Study of Human Corticotropin-Releasing Factor (hCRF)
- Phase I, oral agent for Advanced Cancers
- Randomized Study comparing Human Corticotropin-Releasing Factor to Placebo for Patients Requiring High-dose Dexamethasone
- Weekly IV of Hymcamtin in Combination with Carboplatin as Second Line Therapy in Potentially Platinum-Sensitive Reaplased Ovarian Cancer